Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Polaryx Therapeutics, Inc.PLYX · Entity 6769 | Chief Medical Officer | January 29, 2026 | January 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Polaryx Therapeutics, Inc.
Report date January 29, 2026 · Filed January 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 150,358 |
Reported balance
Holding disclosure · report date 2026-01-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 150,358 F1: Includes 150,000 restricted stock units ("RSUs"), which will vest in four equal installments on November 15, 2026, November 15, 2027, November 15, 2028 and November 15, 2029, subject to the Reporting Person's continued service to the Issuer or its subsidiaries, Mstone Partners Healthcare Limited or its affiliates, or Curestone Partners Platform Limited or its affiliates. The RSUs are not deliverable unless and until the Issuer consummates a change in control within seven years of the grant date of such RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 150,000 restricted stock units ("RSUs"), which will vest in four equal installments on November 15, 2026, November 15, 2027, November 15, 2028 and November 15, 2029, subject to the Reporting Person's continued service to the Issuer or its subsidiaries, Mstone Partners Healthcare Limited or its affiliates, or Curestone Partners Platform Limited or its affiliates. The RSUs are not deliverable unless and until the Issuer consummates a change in control within seven years of the grant date of such RSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apogee Therapeutics, Inc.
Report date September 03, 2026 · Filed September 03, 2026
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.86 · Expires 2034-05-28 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-03 · Disposition to issuer · Disposed 18,550 · Balance 0 F2: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. F1: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.85 · Expires 2034-06-05 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Disposition to issuer · Disposed 8,112 · Balance 0 F2: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. F1: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.66 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 14,461 · Balance 0 F2: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. F1: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.00 · Expires 2036-06-09 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 7,657 · Balance 0 F2: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. F1: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F2: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,657 | Not disclosed Strike: $85.00 | Not disclosed |
DisclosureSEC source: 0001140361-26-035610 · form4.xml · derivative · entry 4 Bollinger Lisa · CIK 0002024557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,657 shares Expires 2036-06-09 F2 · price: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. F1 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F2 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,461 | Not disclosed Strike: $41.66 | Not disclosed |
DisclosureSEC source: 0001140361-26-035610 · form4.xml · derivative · entry 3 Bollinger Lisa · CIK 0002024557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,461 shares Expires 2035-06-17 F2 · price: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. F1 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F2 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,112 | Not disclosed Strike: $43.85 | Not disclosed |
DisclosureSEC source: 0001140361-26-035610 · form4.xml · derivative · entry 2 Bollinger Lisa · CIK 0002024557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,112 shares Expires 2034-06-05 F2 · price: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. F1 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F2 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,550 | Not disclosed Strike: $47.86 | Not disclosed |
DisclosureSEC source: 0001140361-26-035610 · form4.xml · derivative · entry 1 Bollinger Lisa · CIK 0002024557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,550 shares Expires 2034-05-28 F2 · price: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. F1 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F2 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| June 09, 2026 Filed Jun 12, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 7,657 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001104659-26-073056 · tm2617578-4_4seq1.xml · derivative · entry 1 Bollinger Lisa · CIK 0002024557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,657 Underlying: Common Stock · 7,657 shares Expires 2036-06-09 F1 · derivative.exercise_date: This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 21, 2025 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 14,461 | $0.00 Strike: $41.66 | $0.00 |
DisclosureSEC source: 0001104659-25-061272 · tm2518364-4_4seq1.xml · derivative · entry 1 Bollinger Lisa · CIK 0002024557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,461 Underlying: Common Stock · 14,461 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 00:04 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 8,112 | $0.00 Strike: $43.85 | $0.00 |
DisclosureSEC source: 0001104659-24-069797 · tm2416491-5_4seq1.xml · derivative · entry 1 Bollinger Lisa · CIK 0002024557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,112 Underlying: Common Stock · 8,112 shares Expires 2034-06-05 F1 · derivative.exercise_date: This option represents the right to purchase 8,112 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| May 28, 2024 Filed May 31, 2024 00:07 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GrantStock Option (Right to Buy) · Derivative | 18,550 | $0.00 Strike: $47.86 | $0.00 |
DisclosureSEC source: 0001104659-24-066788 · tm2415914-2_4seq1.xml · derivative · entry 1 Bollinger Lisa · CIK 0002024557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,550 Underlying: Common Stock · 18,550 shares Expires 2034-05-28 F1 · derivative.exercise_date: This option represents the right to purchase 18,550 shares of the Issuer's common stock, and will vest in three approximately equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.